Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
GBM
MCID: GLB002
MIFTS: 74

Glioblastoma (GBM)

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Glioblastoma

About this section

MalaCards integrated aliases for Glioblastoma:

Name: Glioblastoma 53 59 29 55 6 73
Glioblastoma Multiforme 53 59 73
Gbm 59

Characteristics:

Orphanet epidemiological data:

59
glioblastoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA360
MESH via Orphanet 45 D005909
UMLS via Orphanet 74 C0017636 C1621958
ICD10 via Orphanet 34 C71.9
Sources

Summaries for Glioblastoma

About this section
NIH Rare Diseases : 53 Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1, Turcot syndrome and Li Fraumeni syndrome. There is currently no cure for glioblastoma. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy.

MalaCards based summary : Glioblastoma, also known as glioblastoma multiforme, is related to glioblastoma multiforme and giant cell glioblastoma, and has symptoms including seizures and headache. An important gene associated with Glioblastoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and TGF-Beta Pathway. The drugs Gliadel Wafer and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are seizures and muscle weakness

Wikipedia : 76 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins... more...

Sources

Related Diseases for Glioblastoma

About this section

Diseases related to Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 479)
# Related Disease Score Top Affiliating Genes
1 glioblastoma multiforme 34.8 EGFR IDH1 MIR137 MIR21 MIR221 MTOR
2 giant cell glioblastoma 34.6 BRAF EGFR FGFR1 IDH1 PTEN TP53
3 gliosarcoma 33.7 EGFR FGFR1 IDH1 PTEN TP53
4 gliomatosis cerebri 33.0 EGFR IDH1 PTEN TP53
5 glioma 31.6 BRAF EGFR FGFR1 IDH1 MIR21 MIR221
6 grade iii astrocytoma 31.4 EGFR PTEN TP53
7 medulloblastoma 31.2 EGFR FGFR1 IDH1 MIR326 MIR34A NRAS
8 oligodendroglioma 31.2 EGFR IDH1 PTEN TP53
9 brain cancer 31.1 BRAF EGFR HRAS IDH1 NRAS PIK3CA
10 pleomorphic xanthoastrocytoma 31.0 BRAF IDH1 TP53
11 neuroblastoma 31.0 FGFR1 MIR221 MIR34A NRAS PIK3CA TP53
12 sarcoma 31.0 BRAF HRAS MTOR PIK3CA TP53
13 melanoma 30.9 BRAF MIR137 MIR182 MIR221 MIR222 MIR34A
14 adenocarcinoma 30.8 BRAF EGFR FGFR1 HRAS PIK3CA PTEN
15 breast cancer 30.8 BRAF EGFR FGFR1 HRAS IDH1 MIR182
16 lung cancer 30.7 BRAF EGFR FGFR1 HRAS MIR137 MIR182
17 prostate cancer 30.6 EGFR FGFR1 HRAS MIR182 MIR21 MIR221
18 pancreatic cancer 30.5 EGFR HRAS MIR21 MIR221 MIR222 MIR34A
19 colorectal cancer 30.5 BRAF EGFR HRAS MIR137 MIR182 MIR21
20 thyroid cancer 30.5 BRAF EGFR HRAS NRAS PIK3CA PTEN
21 hepatocellular carcinoma 30.4 EGFR FGFR1 HRAS IDH1 MIR137 MIR182
22 adamantinoma of long bones 30.4 BRAF EGFR PIK3CA PTEN TP53
23 small cell cancer of the lung 30.4 EGFR MIR21 PIK3CA PTEN TP53
24 li-fraumeni syndrome 30.4 EGFR IDH1 PTEN TP53
25 leukemia, acute lymphoblastic 30.4 MIR21 MIR221 MIR222 MIR451A
26 ovarian cancer 30.4 BRAF EGFR MIR182 MIR21 MIR221 MIR222
27 small cell carcinoma 30.3 EGFR PTEN TP53
28 lung cancer susceptibility 3 30.2 BRAF EGFR HRAS IDH1 NRAS PIK3CA
29 adenoid cystic carcinoma 30.2 BCOR HRAS IDH1 PIK3CA PTEN TP53
30 myeloma, multiple 30.2 BRAF HRAS IDH1 NRAS TP53
31 testicular germ cell tumor 30.2 BRAF HRAS PTEN TP53
32 leukemia, chronic lymphocytic 2 30.2 BRAF HRAS MIR34A NRAS TP53
33 lipomatosis 30.1 FGFR1 PIK3CA PTEN
34 bladder cancer 30.1 EGFR HRAS MIR21 MIR221 MIR222 TP53
35 thyroid cancer, nonmedullary, 1 30.1 BRAF MIR221 MIR222 MIR34A
36 lymphoma, non-hodgkin, familial 30.1 BRAF NRAS PIK3CA TP53
37 myeloid leukemia 30.0 HRAS IDH1 NRAS TP53
38 pancreatic neuroendocrine tumor 29.7 MTOR PIK3CA
39 brain glioblastoma multiforme 12.3
40 glioblastoma proneural subtype 12.3
41 glioblastoma classical subtype 12.2
42 glioblastoma mesenchymal subtype 12.2
43 glioblastoma neural subtype 12.2
44 glioma susceptibility 1 12.2
45 goodpasture syndrome 12.1
46 adult spinal cord glioblastoma multiforme 12.1
47 glioma susceptibility 3 11.7
48 anti-basement membrane glomerulonephritis 11.5
49 mismatch repair cancer syndrome 11.3
50 hematuria, benign familial 11.0

Graphical network of the top 20 diseases related to Glioblastoma:



Diseases related to Glioblastoma
Sources

Symptoms & Phenotypes for Glioblastoma

About this section

Human phenotypes related to Glioblastoma:

59 32 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
2 muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0001324
3 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
4 memory impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002354
5 visual loss 59 32 frequent (33%) Frequent (79-30%) HP:0000572
6 paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0003470
7 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
8 cerebral edema 59 32 frequent (33%) Frequent (79-30%) HP:0002181
9 language impairment 59 32 frequent (33%) Frequent (79-30%) HP:0002463
10 abnormal cell morphology 59 32 hallmark (90%) Very frequent (99-80%) HP:0025461
11 mood changes 59 32 frequent (33%) Frequent (79-30%) HP:0001575
12 abnormality of the cerebral white matter 59 Frequent (79-30%)
13 abnormality of nervous system physiology 59 Frequent (79-30%)
14 abnormality of the corpus callosum 59 Frequent (79-30%)
15 glioblastoma 59 Obligate (100%)
16 glioblastoma multiforme 32 obligate (100%) HP:0012174
17 abnormal corpus callosum morphology 32 frequent (33%) HP:0001273

UMLS symptoms related to Glioblastoma:


seizures, headache

GenomeRNAi Phenotypes related to Glioblastoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.56 EGFR HRAS MTOR PIK3CA BRAF
2 Decreased viability GR00221-A-1 10.56 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
3 Decreased viability GR00221-A-2 10.56 FGFR1 HRAS PIK3CA
4 Decreased viability GR00221-A-3 10.56 HRAS NRAS
5 Decreased viability GR00221-A-4 10.56 EGFR MTOR PIK3CA BRAF
6 Decreased viability GR00301-A 10.56 BRAF
7 Decreased viability GR00342-S-1 10.56 MTOR
8 Decreased viability GR00342-S-2 10.56 MTOR
9 Decreased viability GR00381-A-1 10.56 BRAF
10 Decreased viability GR00402-S-2 10.56 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
11 Decreased cell migration GR00055-A-1 9.72 BRAF EGFR HRAS MTOR PIK3CA
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.65 EGFR HRAS MTOR NRAS PTEN
13 Decreased viability with paclitaxel GR00179-A-1 9.35 EGFR MTOR
14 Decreased viability with paclitaxel GR00179-A-2 9.35 MTOR
15 Decreased viability with paclitaxel GR00179-A-3 9.35 EGFR MTOR
16 Increased cell migration GR00055-A-3 9.02 BRAF EGFR HRAS MTOR PIK3CA

MGI Mouse Phenotypes related to Glioblastoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 BCOR BRAF EGFR FGFR1 HRAS MTOR
2 embryo MP:0005380 10.11 BCOR BRAF EGFR FGFR1 MTOR NRAS
3 endocrine/exocrine gland MP:0005379 10.09 BRAF EGFR FGFR1 HRAS MTOR NRAS
4 integument MP:0010771 10.01 BRAF EGFR FGFR1 HRAS NRAS PIK3CA
5 neoplasm MP:0002006 9.91 BRAF EGFR HRAS NRAS PIK3CA PTEN
6 no phenotypic analysis MP:0003012 9.87 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
7 renal/urinary system MP:0005367 9.7 BRAF EGFR FGFR1 HRAS MTOR PTEN
8 pigmentation MP:0001186 9.65 BRAF EGFR NRAS PTEN TP53
9 respiratory system MP:0005388 9.5 BRAF EGFR HRAS IDH1 MTOR PTEN
10 skeleton MP:0005390 9.32 BRAF EGFR FGFR1 HRAS IDH1 MTOR
Sources

Drugs & Therapeutics for Glioblastoma

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
2
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999

Drugs for Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 600)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
4 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
5 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 100286-90-6, 97682-44-5 60838
8
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
9
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 38904 498142
10
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 6055-19-2, 50-18-0 2907
12
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
13
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1 33419-42-0 36462
14
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
15
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
16
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
17
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
18
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
19
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
20
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 557795-19-4, 341031-54-7 5329102
21
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
22
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
23
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
24
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
25
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
26
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
27
chloroquine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
28
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
29
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
30
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
31
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
32
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
33
Copper Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 7440-50-8 27099
34
Disulfiram Approved Phase 2, Phase 3,Phase 1,Early Phase 1 97-77-8 3117
35
Nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
36
Valproic Acid Approved, Investigational Phase 3,Phase 2,Phase 1 99-66-1 3121
37
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
38
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
39
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
40
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
41
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
42
Povidone Approved Phase 3 9003-39-8
43
Povidone-iodine Approved Phase 3 25655-41-8
44
Dopamine Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
45
Losartan Approved Phase 3 114798-26-4 3961
46
Angiotensin II Approved, Investigational Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
47
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
48
Norepinephrine Approved Phase 3 51-41-2 439260
49
Cyproheptadine Approved Phase 3 129-03-3 2913
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 11103-57-4, 68-26-8 445354

Interventional clinical trials:

(show top 50) (show all 1404)
# Name Status NCT ID Phase Drugs
1 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Unknown status NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
2 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
3 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
4 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
5 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
6 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
7 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
8 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
9 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
10 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
11 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
12 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
13 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
14 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3 nimotuzumab
15 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
16 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
17 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
18 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
19 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
20 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
21 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
22 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
23 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
24 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
25 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
26 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
27 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
28 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
29 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
30 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
31 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
32 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
33 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
34 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
35 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
36 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3 TransMID
37 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
38 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
39 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
40 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
41 Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
42 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
43 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
44 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
45 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
46 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
47 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02685605 Phase 3 Temozolomide
48 A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma Recruiting NCT03345095 Phase 3 Marizomib;Temozolomide
49 Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma Recruiting NCT03632135 Phase 3 Chemotherapy
50 A Study for Management of Ocular Side Effects in Subjects With Glioblastoma Receiving Depatuxizumab Mafodotin Recruiting NCT03419403 Phase 3 Steroid eye drop;Ophthalmic steroid ointment;Temozolomide;depatuxizumab mafodotin;Vasoconstrictor eye drop

Search NIH Clinical Center for Glioblastoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Glioblastoma

About this section

Genetic tests related to Glioblastoma:

# Genetic test Affiliating Genes
1 Glioblastoma 29
Sources

Anatomical Context for Glioblastoma

About this section

MalaCards organs/tissues related to Glioblastoma:

41
Brain, T Cells, Endothelial, Testes, Lung, Spinal Cord, Breast
Sources

Publications for Glioblastoma

About this section

Articles related to Glioblastoma:

(show top 50) (show all 5757)
# Title Authors Year
1
Analyses of temporal and spatial patterns of glioblastoma multiforme and other brain cancer subtypes in relation to mobile phones using synthetic counterfactuals. ( 30384227 )
2019
2
The role of CMV in glioblastoma and implications for immunotherapeutic strategies. ( 30546954 )
2019
3
Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma. ( 30546966 )
2019
4
Tracing the Origin of Glioblastoma: Subventricular Zone Neural Stem Cells. ( 30551194 )
2019
5
Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients. ( 30472587 )
2019
6
miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma. ( 30365062 )
2019
7
MicroRNA‑876‑5p inhibits the progression of glioblastoma multiforme by directly targeting Forkhead box M1. ( 30365126 )
2019
8
Bradykinin B1 receptor contributes to interleukin-8 production and glioblastoma migration through interaction of STAT3 and SP-1. ( 30366000 )
2019
9
AHIF promotes glioblastoma progression and radioresistance via exosomes. ( 30387845 )
2019
10
Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure. ( 30388586 )
2019
11
Isolation and Culture of Glioblastoma Brain Tumor Stem Cells. ( 30324510 )
2019
12
EPH Profiling of BTIC Populations in Glioblastoma Multiforme Using CyTOF. ( 30324522 )
2019
13
Drug Delivery in an Orthotopic Tumor Stem Cell-Based Model of Human Glioblastoma. ( 30324525 )
2019
14
Preparation of superparamagnetic iron oxide/doxorubicin loaded chitosan nanoparticles as a promising glioblastoma theranostic tool. ( 30145790 )
2019
15
Hairless regulates p53 target genes to exert tumor suppressive functions in glioblastoma. ( 30191601 )
2019
16
Glioblastoma multiforme subterfuge as acute cerebral hemorrhage: A case report and literature review. ( 29844891 )
2018
17
Evaluation of the relationship of erythrocyte membrane Na+/K+-ATPase enzyme activity and tumor response to chemoradiotherapy in patients diagnosed with locally advanced nonsmall cell lung cancer and glioblastoma multiforme. ( 29970705 )
2018
18
3-O-acetyl-11-keto-I^-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase. ( 29970196 )
2018
19
Sodium butyrate induces senescence and inhibits the invasiveness of glioblastoma cells. ( 29434841 )
2018
20
BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. ( 29977042 )
2018
21
Benzyl isothiocyanate inhibits human brain glioblastoma multiforme GBM 8401 cell xenograft tumor in nude mice in vivo. ( 29972272 )
2018
22
Highlighting the need for reliable clinical trials in glioblastoma. ( 29973092 )
2018
23
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. ( 29979390 )
2018
24
Venous thromboembolic complications with and without intermittent intraoperative and postoperative pneumatic compression in patients with glioblastoma multiforme using intraoperative magnetic resonance imaging. A retrospective study. ( 29859696 )
2018
25
Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. ( 29385725 )
2018
26
Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival. ( 29434344 )
2018
27
Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles. ( 29963263 )
2018
28
Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes. ( 29444555 )
2018
29
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. ( 29502931 )
2018
30
microRNAa89574 inhibits cell proliferation and invasion in glioblastoma multiforme by directly targeting zinc finger Ea89boxa89binding homeobox 1. ( 29901177 )
2018
31
Specifically Targeted Electromagnetic Fields Arrest Proliferation of Glioblastoma Multiforme U-87 Cells in Culture. ( 29848672 )
2018
32
Enhanced and preferential internalization of lipid nanocapsules into human glioblastoma cells: effect of a surface-functionalizing NFL peptide. ( 29972178 )
2018
33
Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. ( 28926136 )
2018
34
A case of subgaleal metastasis from glioblastoma multiforme. ( 29898273 )
2018
35
MicroRNA-370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating I^-catenin and causing activation of FOXO3a. ( 29399110 )
2018
36
Does radiation therapy increase gadolinium accumulation in the brain?: Quantitative analysis of T1 shortening using R1 relaxometry in glioblastoma multiforme patients. ( 29444157 )
2018
37
Evaluation of Targeted Curcumin (CUR) loaded PLGA Nanoparticles for in vitro Photodynamic Therapy on Human Glioblastoma Cell Line. ( 29969678 )
2018
38
Combining Perfusion and High B-value Diffusion MRI to Inform Prognosis and Predict Failure Patterns in Glioblastoma. ( 29980414 )
2018
39
Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. ( 29953855 )
2018
40
Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. ( 29899827 )
2018
41
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. ( 28266716 )
2018
42
Overexpression of centrosomal protein 55 regulates the proliferation of glioma cell and mediates proliferation promoted by EGFRvIII in glioblastoma U251 cells. ( 29434995 )
2018
43
Long noncoding RNA SNHG7 promotes the progression and growth of glioblastoma via inhibition of miR-5095. ( 29360452 )
2018
44
Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. ( 29416731 )
2018
45
Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. ( 29366782 )
2018
46
Knockdown of RWD domain containing 3 inhibits the malignant phenotypes of glioblastoma cells via inhibition of phosphoinositide 3-kinase/protein kinase B signaling. ( 29977365 )
2018
47
Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. ( 29444930 )
2018
48
Machine Learning-based Texture Analysis of Contrast-enhanced MR Imaging to Differentiate between Glioblastoma and Primary Central Nervous System Lymphoma. ( 29769456 )
2018
49
Hyaluronic Acid-Modified Micelles Encapsulating Gem-C<sub>12</sub>and HNK for Glioblastoma Multiforme Chemotherapy. ( 29397747 )
2018
50
Intraoperative Flow Cytometry Enables the Differentiation of Primary Central Nervous System Lymphoma from Glioblastoma. ( 29330078 )
2018
Sources

Variations for Glioblastoma

About this section

ClinVar genetic disease variations for Glioblastoma:

6 (show top 50) (show all 455)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 GRCh37 Chromosome 10, 89717672: 89717672
2 PTEN NM_000314.6(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 GRCh38 Chromosome 10, 87957915: 87957915
3 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
4 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
7 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
9 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
10 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
11 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
12 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
13 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
14 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
15 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
16 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
17 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
18 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
19 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
20 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
21 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
22 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
23 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
24 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
25 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
26 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
27 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
28 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
29 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
30 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
31 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
32 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
33 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
34 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
35 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
36 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
37 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
38 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
39 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
40 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
42 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
43 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
44 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
45 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
46 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
47 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
48 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
49 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
50 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605

Copy number variations for Glioblastoma from CNVD:

7 (show all 37)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13758 1 1 28000000 Copy number Glioblastoma
2 30312 1 241718157 242073207 Amplification AKT3 Glioblastoma
3 33636 1 46800000 50700000 Copy number Glioblastoma
4 40021 10 123227833 123347962 Amplification FGFR2 Glioblastoma
5 42796 10 40200000 135534747 Loss Glioblastoma
6 51519 11 127400000 130300000 Loss Glioblastoma
7 70074 12 58100000 63100000 Copy number CDK4 Glioblastoma
8 71138 12 67700000 71500000 Copy number MDM2 Glioblastoma
9 74585 13 109204184 109236915 Amplification IRS2 Glioblastoma
10 87860 14 78400000 100400000 Loss Glioblastoma
11 106844 17 1 3600000 Loss Glioblastoma
12 109487 17 26446120 26728821 Deletion NF1 Glioblastoma
13 122049 18 52000000 76117153 Loss Glioblastoma
14 132099 19 57600000 63811651 Gain Glioblastoma
15 133731 19 6900000 13900000 Copy number CDKN2D Glioblastoma
16 137039 2 136600000 209100000 Gain Glioblastoma
17 187590 4 52700000 59500000 Amplification CHIC2 Glioblastoma
18 187591 4 52700000 59500000 Amplification IGFBP7 Glioblastoma
19 187592 4 52700000 59500000 Amplification KDR Glioblastoma
20 187593 4 52700000 59500000 Amplification KIT Glioblastoma
21 187594 4 52700000 59500000 Amplification KIT Glioblastoma
22 187596 4 52700000 59500000 Amplification LNX1 Glioblastoma
23 187597 4 52700000 59500000 Amplification PDGFRA Glioblastoma
24 187598 4 52700000 59500000 Amplification PDGFRA Glioblastoma
25 187599 4 52700000 59500000 Amplification RASL11B Glioblastoma
26 187600 4 52700000 59500000 Amplification REST Glioblastoma
27 187601 4 52700000 59500000 Amplification SEC3L1 Glioblastoma
28 187602 4 52700000 59500000 Amplification USP46 Glioblastoma
29 187603 4 52700000 59500000 Amplification VEGFR2 Glioblastoma
30 187604 4 52700000 59500000 Copy number Glioblastoma
31 207847 6 161688579 163068824 Deletion PARK2 Glioblastoma
32 226025 7 54000000 58000000 Copy number EGFR Glioblastoma
33 226576 7 59600001 66100000 Gain Glioblastoma
34 250055 9 19900000 33200000 Copy number CDKN2A Glioblastoma
35 253823 9 4600000 14200000 Deletion PTPRD Glioblastoma
36 253952 9 49000000 141213431 Loss Glioblastoma
37 255680 9 8304245 10602723 Deletion PTPRD Glioblastoma
Sources

Expression for Glioblastoma

About this section
Search GEO for disease gene expression data for Glioblastoma.
Sources

Pathways for Glioblastoma

About this section

Pathways related to Glioblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Super pathways Score Top Affiliating Genes
1
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 66
Show member pathways